Quest Laboratories Ltd.
NNSE:QUESTLAB87.40
INR
-2.80
(-3.10%)
Quest Laboratories Ltd.
NSE:QUESTLAB
(National Stock Exchange of India)
Recent
price
87.40
P/E
ratio
24.93
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Quest Laboratories Ltd (QUESTLAB.NS) manufactures pharmaceutical formulations across diverse therapeutic categories, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and other essential medicines. The company produces ethical drugs, generic drugs, and over-the-counter (OTC) products in various dosage forms such as uncoated, film-coated, enteric-coated, and sustained-release tablets; liquid orals including syrups, elixirs, and suspensions; dry syrups; oral powders and oral rehydration salts (ORS); liquid externals like antiseptics and sanitizers; ointments and creams; capsules (soft gelatin and hard gelatin); ampoules; and injection vials. It holds approvals for over 900 formulations, operates more than 800 licensed formulations and 272 active products, and provides institutional supplies, domestic ethical marketing, PCD (propaganda-cum-distribution), contract manufacturing, and export services with WHO GMP, Schedule M GMP, and GLP certifications. Incorporated on June 1, 1998, as Quest Laboratories Pvt. Ltd. and later converted to a public limited company, Quest Laboratories Ltd maintains its headquarters and manufacturing facility in Dhar, Madhya Pradesh, India. The company serves the domestic market across 12 states and two union territories, including Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal, Gujarat, Telangana, and Haryana, with live rate contracts from medical corporations in Uttar Pradesh, Madhya Pradesh, and Jammu. It is expanding into exports, supported by an order book exceeding INR 25 crore from Myanmar, and recently added Bihar and Jharkhand through tender participation. In recent developments, the company approved audited standalone financial results for FY25 (ended March 2025) on August 18, 2025, reflecting revenue growth to INR 104 crore and profit after tax of INR 14 crore, alongside appointments of internal, secretarial, and cost auditors for FY26. On September 4, 2025, it announced the resignation of Company Secretary Surabhi Gupta effective September 3, 2025, and appointed Mrs. Ayushi Taunk, with over six years of experience, as the new Company Secretary and Compliance Officer. An Annual General Meeting is scheduled for September 29, 2025, to adopt FY25 financials, reappoint director Anil Kumar Sabarwal, and approve auditors; additionally, in 2023-2024, production capacity expanded with new liquid oral lines (1 lakh bottles per day) and tablet lines (40 lakh tablets per day), geared up by October 2023, while plans advance for a state-of-the-art injectable plant focused on oncology in 2024-2025.